Elanco Animal Health (NYSE:ELAN) Price Target Raised to $35.00

Elanco Animal Health (NYSE:ELAN) had its price objective hoisted by JPMorgan Chase & Co. from $33.00 to $35.00 in a research report sent to investors on Monday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

ELAN has been the topic of several other reports. KeyCorp reissued an “overweight” rating on shares of Elanco Animal Health in a research note on Monday. The Goldman Sachs Group initiated coverage on Elanco Animal Health in a research report on Friday, October 16th. They issued a “buy” rating and a $32.00 price objective on the stock. Weiss Ratings raised Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. Jefferies Financial Group downgraded Elanco Animal Health from a “buy” rating to a “hold” rating and dropped their target price for the stock from $31.00 to $24.00 in a research report on Tuesday, October 20th. Finally, UBS Group upped their price target on Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $29.75.

Elanco Animal Health Stock Performance

NYSE ELAN opened at $26.52 on Monday. The firm has a market cap of $13.25 billion, a price-to-earnings ratio of -88.38, a PEG ratio of 2.26 and a beta of 1.73. Elanco Animal Health has a 1-year low of $19.40 and a 1-year high of $27.98. The company has a 50 day moving average of $23.29 and a 200-day moving average of $23.86. The company has a current ratio of 2.09, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Friday, November 6th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.20 by $0.07. The firm had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.21 billion. Elanco Animal Health had a positive return on equity of 8.80% and a negative net margin of 2.86%. The business’s revenue was up 11.3% on a year-over-year basis. During the same period last year, the firm posted $0.19 EPS. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. On average, equities analysts forecast that Elanco Animal Health will post 1.18 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Elanco Animal Health news, Director Lawrence Kurzius acquired 40,000 shares of the business’s stock in a transaction that occurred on Thursday, August 20th. The shares were acquired at an average cost of $23.40 per share, for a total transaction of $936,000.00. Following the completion of the acquisition, the director directly owned 188,647 shares of the company’s stock, valued at approximately $4,414,339.80. This represents a 26.91% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Shiv O’Neill acquired 3,998 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was acquired at an average price of $23.58 per share, for a total transaction of $94,272.84. Following the completion of the acquisition, the insider directly owned 87,832 shares of the company’s stock, valued at $2,071,078.56. This trade represents a 4.77% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 1.14% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Elanco Animal Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ELAN. Anchor Investment Management LLC acquired a new stake in shares of Elanco Animal Health in the 2nd quarter valued at approximately $29,000. Covestor Ltd grew its holdings in Elanco Animal Health by 48.2% during the third quarter. Covestor Ltd now owns 1,383 shares of the company’s stock valued at $31,000 after purchasing an additional 450 shares during the period. Integrated Wealth Concepts LLC bought a new stake in Elanco Animal Health in the second quarter valued at approximately $35,000. Fulcrum Asset Management LLP bought a new stake in Elanco Animal Health in the third quarter valued at approximately $36,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Elanco Animal Health in the second quarter worth $38,000. Institutional investors own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health is a global animal health company that develops, manufactures and markets products for companion animals and livestock. Its offerings include medicines, vaccines and other products intended to prevent and treat disease and support animal health. For pets, Elanco provides treatments for conditions including parasitic infections, pain and chronic diseases. Its livestock products support the health of animals such as cattle, poultry, swine and fish, serving producers and veterinarians.